HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials

Herpes simplex virus 1 (HSV-1) provides a genetic chassis for several oncolytic viruses (OVs) currently in clinical trials. Oncolytic HSV1 (oHSV) have been engineered to reduce neurovirulence and enhance anti-tumor lytic activity and immunogenicity to make them attractive candidates in a range of on...

Full description

Bibliographic Details
Main Authors: Marilin S. Koch, Sean E. Lawler, E. Antonio Chiocca
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/12/12/3514
id doaj-990f466362a04edab2ebb1b847708440
record_format Article
spelling doaj-990f466362a04edab2ebb1b8477084402020-11-27T08:07:39ZengMDPI AGCancers2072-66942020-11-01123514351410.3390/cancers12123514HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical TrialsMarilin S. Koch0Sean E. Lawler1E. Antonio Chiocca2Harvey Cushing Neurooncology Research Laboratories, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAHarvey Cushing Neurooncology Research Laboratories, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAHarvey Cushing Neurooncology Research Laboratories, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USAHerpes simplex virus 1 (HSV-1) provides a genetic chassis for several oncolytic viruses (OVs) currently in clinical trials. Oncolytic HSV1 (oHSV) have been engineered to reduce neurovirulence and enhance anti-tumor lytic activity and immunogenicity to make them attractive candidates in a range of oncology indications. Successful clinical data resulted in the FDA-approval of the oHSV talimogene laherparepvec (T-Vec) in 2015, and several other variants are currently undergoing clinical assessment and may expand the landscape of future oncologic therapy options. This review offers a detailed overview of the latest results from clinical trials as well as an outlook on newly developed HSV-1 oncolytic variants with improved tumor selectivity, replication, and immunostimulatory capacity and related clinical studies.https://www.mdpi.com/2072-6694/12/12/3514HSV-1oncolytic virusimmunotherapyclinical trials
collection DOAJ
language English
format Article
sources DOAJ
author Marilin S. Koch
Sean E. Lawler
E. Antonio Chiocca
spellingShingle Marilin S. Koch
Sean E. Lawler
E. Antonio Chiocca
HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
Cancers
HSV-1
oncolytic virus
immunotherapy
clinical trials
author_facet Marilin S. Koch
Sean E. Lawler
E. Antonio Chiocca
author_sort Marilin S. Koch
title HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
title_short HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
title_full HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
title_fullStr HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
title_full_unstemmed HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials
title_sort hsv-1 oncolytic viruses from bench to bedside: an overview of current clinical trials
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2020-11-01
description Herpes simplex virus 1 (HSV-1) provides a genetic chassis for several oncolytic viruses (OVs) currently in clinical trials. Oncolytic HSV1 (oHSV) have been engineered to reduce neurovirulence and enhance anti-tumor lytic activity and immunogenicity to make them attractive candidates in a range of oncology indications. Successful clinical data resulted in the FDA-approval of the oHSV talimogene laherparepvec (T-Vec) in 2015, and several other variants are currently undergoing clinical assessment and may expand the landscape of future oncologic therapy options. This review offers a detailed overview of the latest results from clinical trials as well as an outlook on newly developed HSV-1 oncolytic variants with improved tumor selectivity, replication, and immunostimulatory capacity and related clinical studies.
topic HSV-1
oncolytic virus
immunotherapy
clinical trials
url https://www.mdpi.com/2072-6694/12/12/3514
work_keys_str_mv AT marilinskoch hsv1oncolyticvirusesfrombenchtobedsideanoverviewofcurrentclinicaltrials
AT seanelawler hsv1oncolyticvirusesfrombenchtobedsideanoverviewofcurrentclinicaltrials
AT eantoniochiocca hsv1oncolyticvirusesfrombenchtobedsideanoverviewofcurrentclinicaltrials
_version_ 1724413723887534080